AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 29701288 — intervention group
Group type: EXPERIMENTAL
Intervention: BAHS implantation using linear incision technique with soft‐tissue preservation
Number of subjects: 35
Study 29701288 — intervention group
Group type: COMPARATOR
Intervention: Inflammation episodes
Number of subjects: 35
Study 28502243 — intervention group
Group type: EXPERIMENTAL
Intervention: Targeted training in illness management (TTIM)
Number of subjects: 200
Study 28502243 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 200
Study 24118914 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate occlusal loading
Number of subjects: 19
Study 24118914 — intervention group
Group type: COMPARATOR
Intervention: Non-occlusal loading (control)
Number of subjects: 19
Study 24160371 — intervention group
Group type: EXPERIMENTAL
Intervention: Pelvic floor muscle training for prolapse
Number of subjects: 50
Study 24160371 — intervention group
Group type: EXPERIMENTAL
Intervention: A process for Decision-making after Pilot and feasibility Trials (ADePT)
Number of subjects: 50
Study 21949149 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapid nasogastric rehydration (RNR) over 4 hours in the ED
Number of subjects: 254
Study 21949149 — intervention group
Group type: COMPARATOR
Intervention: Standard nasogastric rehydration (SNR) over 24 hours in the hospital ward
Number of subjects: 254
Study 18382339 — intervention group
Group type: EXPERIMENTAL
Intervention: Low boric acid-containing rewetting drops
Number of subjects: 0
Study 18382339 — intervention group
Group type: EXPERIMENTAL
Intervention: High boric acid-containing rewetting drops
Number of subjects: 0
Study 16873325 — intervention group
Group type: EXPERIMENTAL
Intervention: Usual conservative treatment (UT)
Number of subjects: 200
Study 16873325 — intervention group
Group type: EXPERIMENTAL
Intervention: UT plus a conventional flat-plane hard acrylic splint (HS)
Number of subjects: 200
Study 16873325 — intervention group
Group type: EXPERIMENTAL
Intervention: UT plus a soft vinyl splint (SS)
Number of subjects: 200
Study 16873325 — intervention group
Group type: COMPARATOR
Intervention: HS versus SS
Number of subjects: 200
Study 16873325 — intervention group
Group type: COMPARATOR
Intervention: Self-care treatment without splint therapy (UT)
Number of subjects: 200
Study 12644522 — intervention group
Group type: EXPERIMENTAL
Intervention: Lateral‐medial area index
Number of subjects: 105
Study 12644522 — intervention group
Group type: EXPERIMENTAL
Intervention: Lateral‐medial force index
Number of subjects: 105
Study 12644522 — intervention group
Group type: EXPERIMENTAL
Intervention: Lateral‐medial area index and lateral‐medial force index
Number of subjects: 105
Study 10672051 — intervention group
Group type: EXPERIMENTAL
Intervention: PCM-7 (7 days of pantoprazole 40 mg bid, clarithromycin 500 mg bid, metronidazole 500 mg bid)
Number of subjects: 213
Study 10672051 — intervention group
Group type: EXPERIMENTAL
Intervention: PCM-14 m (modified 14 day therapy with metronidazole only given for 10 days)
Number of subjects: 213
Study 10672051 — intervention group
Group type: EXPERIMENTAL
Intervention: Both PCM-7 and PCM-14 m
Number of subjects: 213
Study 9280742 — intervention group
Group type: EXPERIMENTAL
Intervention: Tramadol hydrochloride 100 mg p.o. or i.m. for moderate to intense pain
Number of subjects: 102
Study 8149141 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg acyclovir orally four times daily during induction therapy
Number of subjects: 107
Study 8149141 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 107
Study 3521240 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin 500 mg
Number of subjects: 3
Study 3521240 — intervention group
Group type: EXPERIMENTAL
Intervention: Dipyrone 575 mg
Number of subjects: 3
Study 3521240 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin 25 mg
Number of subjects: 3
Study 3521240 — intervention group
Group type: EXPERIMENTAL
Intervention: Naproxen 500 mg
Number of subjects: 3
Study 3521240 — intervention group
Group type: COMPARATOR
Intervention: Paracetamol 500 mg
Number of subjects: 3
Study 3521240 — intervention group
Group type: COMPARATOR
Intervention: Tartrazine 50 mg
Number of subjects: 3
Study 3521240 — intervention group
Group type: COMPARATOR
Intervention: Lactose (placebo)
Number of subjects: 3
Study 29498050 — intervention group
Group type: EXPERIMENTAL
Intervention: Granulocyte transfusion therapy plus antimicrobials
Number of subjects: 114
Study 29498050 — intervention group
Group type: COMPARATOR
Intervention: Antimicrobials alone
Number of subjects: 114
Study 27687354 — intervention group
Group type: EXPERIMENTAL
Intervention: Prone position (P)
Number of subjects: 78
Study 27687354 — intervention group
Group type: EXPERIMENTAL
Intervention: Sitting position (S)
Number of subjects: 78
Study 27687354 — intervention group
Group type: COMPARATOR
Intervention: Flexed lateral position (L)
Number of subjects: 78
Study 24757084 — intervention group
Group type: EXPERIMENTAL
Intervention: Ivabradine (Iva) 5 mg BID
Number of subjects: 334
Study 24757084 — intervention group
Group type: COMPARATOR
Intervention: Atenolol (Aten) 12.5 mg BID
Number of subjects: 334
Study 24757084 — intervention group
Group type: EXPERIMENTAL
Intervention: Ivabradine (Iva)
Number of subjects: 334
Study 24757084 — intervention group
Group type: COMPARATOR
Intervention: Atenolol (Aten)
Number of subjects: 334
Study 22493914 — intervention group
Group type: EXPERIMENTAL
Intervention: Aconite cake-separated moxibustion therapy with acupoints (Danzhong (CV 17), Zhongwan (CV 12), Guanyuan (CV 4), Dazhui (GV 14), Shenshu (BL 23), Mingmen (GV 4)) and oral administration of 25 microg Euthyrox everyday
Number of subjects: 85
Study 22493914 — intervention group
Group type: COMPARATOR
Intervention: Oral administration of 25 microg Euthyrox everyday
Number of subjects: 85
Study 20537841 — intervention group
Group type: EXPERIMENTAL
Intervention: Mass media interventions consisting of specially developed messages based on behavioral theory targeted to defined age groups, placed in popular TV, cable, and radio programming for 4 years.
Number of subjects: 19966
Study 20537841 — intervention group
Group type: EXPERIMENTAL
Intervention: Mass media interventions
Number of subjects: 19966
Study 20537841 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 19966
Study 19053917 — intervention group
Group type: COMPARATOR
Intervention: DFDBA alone
Number of subjects: 32
Study 19053917 — intervention group
Group type: EXPERIMENTAL
Intervention: DFDBA combined with EMD
Number of subjects: 32
Study 15672076 — intervention group
Group type: EXPERIMENTAL
Intervention: JC‐EUS
Number of subjects: 40
Study 15672076 — intervention group
Group type: COMPARATOR
Intervention: C‐EUS
Number of subjects: 40
Study 12826990 — intervention group
Group type: EXPERIMENTAL
Intervention: Naltrexone 50 mg/day
Number of subjects: 23
Study 12826990 — intervention group
Group type: EXPERIMENTAL
Intervention: Naltrexone 100 mg/day
Number of subjects: 23
Study 12826990 — intervention group
Group type: EXPERIMENTAL
Intervention: Acamprosate 2 g/day
Number of subjects: 23
Study 12826990 — intervention group
Group type: EXPERIMENTAL
Intervention: Acamprosate 3 g/day
Number of subjects: 23
Study 12826990 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined treatment (Naltrexone and Acamprosate)
Number of subjects: 23
Study 12826990 — intervention group
Group type: EXPERIMENTAL
Intervention: Naltrexone
Number of subjects: 23
Study 12826990 — intervention group
Group type: EXPERIMENTAL
Intervention: Acamprosate
Number of subjects: 23
Study 12826990 — intervention group
Group type: EXPERIMENTAL
Intervention: Naltrexone and Acamprosate (both alone and in combination)
Number of subjects: 23
Study 12826990 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined medications
Number of subjects: 23
Study 10821210 — intervention group
Group type: EXPERIMENTAL
Intervention: Day-long ad lib smoking session
Number of subjects: 25
Study 10821210 — intervention group
Group type: COMPARATOR
Intervention: Overnight smoking abstinence session
Number of subjects: 25
Study 10821210 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol pre-load (9 oz or 270 ml of beer)
Number of subjects: 25
Study 10821210 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking session
Number of subjects: 25
Study 8888301 — intervention group
Group type: EXPERIMENTAL
Intervention: Superordinate relationships affecting perceptual judgments
Number of subjects: 0
Study 8888301 — intervention group
Group type: EXPERIMENTAL
Intervention: Perceptual distortions
Number of subjects: 0
Study 8888301 — intervention group
Group type: EXPERIMENTAL
Intervention: Propositional rules
Number of subjects: 0
Study 1710922 — intervention group
Group type: EXPERIMENTAL
Intervention: Induction chemotherapy with eight cycles of MOPP
Number of subjects: 192
Study 1710922 — intervention group
Group type: COMPARATOR
Intervention: Combination of MOPP and ABVD
Number of subjects: 192
Study 1710922 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiotherapy after partial response
Number of subjects: 192
Study 1710922 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall treatment (including both arms)
Number of subjects: 192
Study 1710922 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment of relapsed patients
Number of subjects: 192
Study 1710922 — intervention group
Group type: EXPERIMENTAL
Intervention: Complete remission (achieved by any means)
Number of subjects: 192
Study 1710922 — intervention group
Group type: EXPERIMENTAL
Intervention: Progression of disease
Number of subjects: 192
Study 1710922 — intervention group
Group type: EXPERIMENTAL
Intervention: Relapses
Number of subjects: 192
Study 6634077 — intervention group
Group type: EXPERIMENTAL
Intervention: High intensity light
Number of subjects: 133
Study 6634077 — intervention group
Group type: COMPARATOR
Intervention: Lower illumination
Number of subjects: 133
Study 31441863 — intervention group
Group type: EXPERIMENTAL
Intervention: Infrared laser moxibustion (ILM)
Number of subjects: 0
Study 31441863 — intervention group
Group type: COMPARATOR
Intervention: Sham infrared laser moxibustion (SILM)
Number of subjects: 0
Study 31441863 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control (WLC)
Number of subjects: 0
Study 29370829 — intervention group
Group type: EXPERIMENTAL
Intervention: Text4Heart II intervention (24-week personalized text message program)
Number of subjects: 330
Study 29370829 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 330
Study 27422220 — intervention group
Group type: EXPERIMENTAL
Intervention: US-guided IV placement
Number of subjects: 59
Study 27422220 — intervention group
Group type: COMPARATOR
Intervention: SOC palpation IV technique
Number of subjects: 59
Study 24112096 — intervention group
Group type: EXPERIMENTAL
Intervention: Buprenorphine-naloxone induction
Number of subjects: 69
Study 21942692 — intervention group
Group type: EXPERIMENTAL
Intervention: First-line antiretroviral (ARV) treatment
Number of subjects: 386
Study 21942692 — intervention group
Group type: EXPERIMENTAL
Intervention: Second-line regimen proposed by WHO (2010) including zidovudine, tenofovir, lopinavir, and atazanavir
Number of subjects: 386
Study 21942692 — intervention group
Group type: EXPERIMENTAL
Intervention: Genotypic resistance testing
Number of subjects: 386
Study 21119104 — intervention group
Group type: COMPARATOR
Intervention: Chest radiograph screening
Number of subjects: 53456
Study 21119104 — intervention group
Group type: EXPERIMENTAL
Intervention: Computerized tomography screening
Number of subjects: 53456
Study 17559147 — intervention group
Group type: EXPERIMENTAL
Intervention: Metronomic chemotherapy with elevated serum HER-2/neu levels (>15 ng/mL) before treatment
Number of subjects: 135
Study 17559147 — intervention group
Group type: EXPERIMENTAL
Intervention: Metronomic chemotherapy with elevated serum HER-2/neu levels at 2 months
Number of subjects: 135
Study 17559147 — intervention group
Group type: EXPERIMENTAL
Intervention: Metronomic chemotherapy with changes in HER-2/neu levels between baseline and 2 months
Number of subjects: 135
Study 17559147 — intervention group
Group type: EXPERIMENTAL
Intervention: Metronomic chemotherapy with >or=20% increase of serum HER-2/neu
Number of subjects: 135
Study 17559147 — intervention group
Group type: EXPERIMENTAL
Intervention: Metronomic chemotherapy with kinetics of serum HER-2/neu
Number of subjects: 135
Study 17559147 — intervention group
Group type: EXPERIMENTAL
Intervention: Metronomic chemotherapy with low baseline serum levels of EGFR (<45 ng/mL)
Number of subjects: 135
Study 17559147 — intervention group
Group type: EXPERIMENTAL
Intervention: Metronomic chemotherapy with low baseline serum levels of EGFR
Number of subjects: 135
Study 16618317 — intervention group
Group type: EXPERIMENTAL
Intervention: Versajet Hydrosurgery System
Number of subjects: 68
Study 16618317 — intervention group
Group type: COMPARATOR
Intervention: Traditional debridement with moist dressings
Number of subjects: 68
Study 11955464 — intervention group
Group type: EXPERIMENTAL
Intervention: Yohimbine (.4 mg/kg, IV)
Number of subjects: 17
Study 11955464 — intervention group
Group type: EXPERIMENTAL
Intervention: Yohimbine
Number of subjects: 17
Study 10691066 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-carotene (50 mg on alternate days)
Number of subjects: 15000
Study 10691066 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin E
Number of subjects: 15000
Study 10691066 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin C
Number of subjects: 15000
Study 10691066 — intervention group
Group type: EXPERIMENTAL
Intervention: Multivitamins
Number of subjects: 15000
Study 10691066 — intervention group
Group type: EXPERIMENTAL
Intervention: Antioxidant vitamins
Number of subjects: 15000
Study 9484152 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceramic tooth simulator
Number of subjects: 0
Study 9484152 — intervention group
Group type: COMPARATOR
Intervention: Natural tooth simulator
Number of subjects: 0
Study 9484152 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dexterity students
Number of subjects: 0
Study 9484152 — intervention group
Group type: EXPERIMENTAL
Intervention: MOD onlay preparation
Number of subjects: 0
Study 9484152 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceramic teeth
Number of subjects: 0
Study 1555273 — intervention group
Group type: EXPERIMENTAL
Intervention: Lovastatin 80 mg/day
Number of subjects: 8245
Study 3926042 — intervention group
Group type: EXPERIMENTAL
Intervention: Infusion of morphine
Number of subjects: 30
Study 3926042 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 30
Study 30894587 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional MRI measurements
Number of subjects: 236
Study 30894587 — intervention group
Group type: EXPERIMENTAL
Intervention: DWI MRI measurements
Number of subjects: 236
Study 30894587 — intervention group
Group type: COMPARATOR
Intervention: Conventional model with DWI measurements
Number of subjects: 236
Study 29292308 — intervention group
Group type: EXPERIMENTAL
Intervention: AAR and telephone-based behavioral counseling
Number of subjects: 327
Study 29292308 — intervention group
Group type: COMPARATOR
Intervention: AAR and attention control (nutrition education)
Number of subjects: 327
Study 27006306 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychological skills training (D6)
Number of subjects: 23
Study 27006306 — intervention group
Group type: COMPARATOR
Intervention: Control intervention (no psychological element)
Number of subjects: 23
Study 24881497 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonantibiotic, alcohol-based antiseptic
Number of subjects: 39
Study 24881497 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 39
Study 22245769 — intervention group
Group type: EXPERIMENTAL
Intervention: Tetrahydrobiopterin (BH(4)) administration
Number of subjects: 24
Study 22245769 — intervention group
Group type: COMPARATOR
Intervention: Transdermal estradiol
Number of subjects: 24
Study 22245769 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 20297613 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxycodone/acetaminophen (5 mg/325 mg, titrated for pain relief)
Number of subjects: 29
Study 20297613 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxycodone/acetaminophen (mean daily dose 13.8 mg/720.4 mg)
Number of subjects: 29
Study 18685961 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal thoracic analgesia (ITA) with levobupivacaine 0.25%, at 0.5-0.7 ml/h, and a single bolus of morphine 0.15 mg
Number of subjects: 60
Study 18685961 — intervention group
Group type: COMPARATOR
Intervention: Epidural thoracic analgesia (ETA) with levobupivacaine 0.25% 4-6 ml/h and a single bolus of epidural morphine 2-3 mg
Number of subjects: 60
Study 15741443 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone 500 mug twice daily
Number of subjects: 86
Study 15741443 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 86
Study 12515837 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive behavior therapy (6 weekly sessions)
Number of subjects: 61
Study 12515837 — intervention group
Group type: COMPARATOR
Intervention: Supportive psychotherapy (6 weekly sessions)
Number of subjects: 61
Study 10916110 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrosoluble vitamins (DiaVite) supplementation once daily by mouth
Number of subjects: 168
Study 10916110 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous folic acid (10 mg posthemodialysis, 30 mg per week) in addition to DiaVite
Number of subjects: 168
Study 10916110 — intervention group
Group type: COMPARATOR
Intervention: Hydrosoluble vitamins (DiaVite) supplementation
Number of subjects: 168
Study 10916110 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous folic acid (10 mg posthemodialysis, 30 mg per week)
Number of subjects: 168
Study 8873685 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifampin (300 mg b.i.d. for 7 days)
Number of subjects: 15
Study 8873685 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythromycin (250 mg q.i.d. for 7 days)
Number of subjects: 15
Study 1647387 — intervention group
Group type: EXPERIMENTAL
Intervention: Interactive information system with instructional video programs, feedback on purchases, specific goals for change, weekly programs, and tracking user interactions; duration: 7-8 weeks intervention phase after a 5-7 week baseline phase.
Number of subjects: 0
Study 1647387 — intervention group
Group type: COMPARATOR
Intervention: Control condition; duration: 7-8 weeks intervention phase after a 5-7 week baseline phase.
Number of subjects: 0
Study 30183743 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifaximin‐α (n = 36)
Number of subjects: 54
Study 30183743 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 18)
Number of subjects: 54
Study 27287439 — intervention group
Group type: EXPERIMENTAL
Intervention: Ovaleap® (recombinant human follicle-stimulating hormone) administered for up to 2 additional cycles
Number of subjects: 208
Study 24561149 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcatheter aortic valve replacement (TAVR)
Number of subjects: 699
Study 24561149 — intervention group
Group type: COMPARATOR
Intervention: Surgical aortic valve replacement (SAVR)
Number of subjects: 699
Study 22278714 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-operative examination with cervical traction
Number of subjects: 81
Study 22278714 — intervention group
Group type: COMPARATOR
Intervention: Pre-operative examination without cervical traction
Number of subjects: 81
Study 20544673 — intervention group
Group type: EXPERIMENTAL
Intervention: Brimonidine tartrate 0.2%
Number of subjects: 78
Study 20544673 — intervention group
Group type: COMPARATOR
Intervention: Artificial tears (Control)
Number of subjects: 78
Study 18391711 — intervention group
Group type: EXPERIMENTAL
Intervention: Meperidine-impregnated autogenous free fat grafts (AFFGs) in the epidural area
Number of subjects: 27
Study 18391711 — intervention group
Group type: COMPARATOR
Intervention: Control group received graft without meperidine impregnation
Number of subjects: 27
Study 15984397 — intervention group
Group type: EXPERIMENTAL
Intervention: System E (gelatin/pectin-based skin barrier with adhesive coupling technology)
Number of subjects: 39
Study 15984397 — intervention group
Group type: EXPERIMENTAL
Intervention: System E
Number of subjects: 39
Study 15984397 — intervention group
Group type: COMPARATOR
Intervention: System F (grooved base plate wafer adhesive pouch coupling system)
Number of subjects: 39
Study 12795776 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebivolol 5 mg
Number of subjects: 24
Study 12795776 — intervention group
Group type: EXPERIMENTAL
Intervention: Bisoprolol 10 mg
Number of subjects: 24
Study 12795776 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol 50 mg
Number of subjects: 24
Study 12795776 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol 100 mg
Number of subjects: 24
Study 12795776 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 10325838 — intervention group
Group type: EXPERIMENTAL
Intervention: Neostigmine in patients pretreated with MgSO4 (group A)
Number of subjects: 12
Study 10325838 — intervention group
Group type: COMPARATOR
Intervention: Neostigmine in patients receiving saline (group B)
Number of subjects: 12
Study 10325838 — intervention group
Group type: EXPERIMENTAL
Intervention: Assisted recovery in MgSO4 pretreated patients (group C)
Number of subjects: 12
Study 10325838 — intervention group
Group type: COMPARATOR
Intervention: Assisted recovery in controls (group D)
Number of subjects: 12
Study 8953337 — intervention group
Group type: EXPERIMENTAL
Intervention: 6.9% glucose-polymer (GP) solution
Number of subjects: 20
Study 8953337 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 1745853 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine 10 mg
Number of subjects: 17
Study 1745853 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine 20 mg
Number of subjects: 17
Study 1745853 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study 6886965 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol (low dose)
Number of subjects: 0
Study 6886965 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol (high dose)
Number of subjects: 0
Study 6886965 — intervention group
Group type: COMPARATOR
Intervention: Alcohol (placebo)
Number of subjects: 0
Study 6886965 — intervention group
Group type: COMPARATOR
Intervention: Nonalcoholic beverage (tonic water)
Number of subjects: 0
Study 6886965 — intervention group
Group type: EXPERIMENTAL
Intervention: Instructional set (regardless of drink content)
Number of subjects: 0
Study 6886965 — intervention group
Group type: EXPERIMENTAL
Intervention: Locus of control (externalizers)
Number of subjects: 0
Study 6886965 — intervention group
Group type: EXPERIMENTAL
Intervention: Locus of control (internalizers)
Number of subjects: 0
Study 31813942 — intervention group
Group type: EXPERIMENTAL
Intervention: Equia Fil/Equia Coat
Number of subjects: 34